Valuation: Krystal Biotech, Inc.

Market Cap 9.84B 8.81B 8.1B 7.34B 13.72B 934B 13.98B 96.62B 38.79B 491B 36.91B 36.13B 1,549B P/E 2026 *
45.7x
P/E 2027 * 36.8x
Enterprise Value 9.22B 8.26B 7.6B 6.89B 12.87B 876B 13.11B 90.63B 36.38B 461B 34.62B 33.88B 1,453B EV / Sales 2026 *
18.6x
EV / Sales 2027 * 13.9x
Free-Float
89.34%
Yield 2026 *
-
Yield 2027 * -
1 day+2.38%
1 week+6.67%
1 month-0.08%
3 months-2.59%
6 months+26.70%
Current year+34.78%
1 week 309.63
Extreme 309.63
332.63
1 month 309.63
Extreme 309.63
339.69
Current year 235.6
Extreme 235.605
382.54
1 year 184.02
Extreme 184.02
382.54
3 years 93.95
Extreme 93.95
382.54
5 years 38.86
Extreme 38.8563
382.54
10 years 8.03
Extreme 8.03
382.54
Manager TitleAgeSince
Chief Operating Officer 61 15/04/2016
Chief Executive Officer 61 15/04/2016
Investor Relations Contact - -
Director TitleAgeSince
Chairman 61 15/04/2016
Director/Board Member 61 15/04/2016
Director/Board Member 60 01/11/2016
Date Insider Type Main position Quantity % Market Cap. Importance
9/14/26 A Free

Director

1,658 0.0056%
9/14/26 A Free

Director

1,658 0.0056%
9/14/26 A Free

Director

1,658 0.0056%
Change 5-day change 1-year change 3-year change Capi.($)
+2.38%+6.67%+68.24%+184.32% 9.84B
+3.19%+11.31%+64.28%+155.91% 1,263B
-0.73%+3.56%+44.65%+84.17% 658B
+1.41%+3.24%+35.25%+108.88% 521B
+0.42%+3.20%+55.81%+72.50% 391B
+2.18%+2.93%+73.90%+45.59% 369B
+1.12%+4.52%+34.76%+58.24% 307B
+6.96%+8.86%+11.95%+36.20% 290B
+1.15%+6.09%+56.15%+82.25% 252B
+3.06%+9.38%+42.48%+117.32% 212B
Average +2.11%+5.98%+48.75%+94.54% 427.18B
Weighted average by Cap. +2.01%+6.60%+50.55%+100.63%

Financials

2026 *2027 *
Net sales 497M 445M 409M 371M 693M 47.16B 706M 4.88B 1.96B 24.81B 1.86B 1.82B 78.24B 634M 568M 522M 473M 885M 60.22B 901M 6.23B 2.5B 31.68B 2.38B 2.33B 99.9B
Net income 225M 202M 186M 168M 314M 21.38B 320M 2.21B 888M 11.25B 845M 827M 35.47B 291M 260M 239M 217M 406M 27.6B 413M 2.86B 1.15B 14.52B 1.09B 1.07B 45.78B
Net Debt -610M -547M -503M -456M -852M -57.97B -868M -6B -2.41B -30.49B -2.29B -2.24B -96.16B -1.02B -913M -840M -761M -1.42B -96.82B -1.45B -10.02B -4.02B -50.93B -3.83B -3.75B -161B
Projected Income Statement - Annual - Krystal Biotech, Inc.
Logo Krystal Biotech, Inc.
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
Employees
295
Date Price Change Volume
30/10/26 $332.29 +2.38% 330,314
29/10/26 $324.55 +0.97% 190,768
28/10/26 $321.42 +0.26% 199,841
27/10/26 $320.58 +2.21% 212,808
26/10/26 $313.66 +0.69% 223,645
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Krystal Biotech, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
332.29USD
Average target price
395.44USD
Spread / Average Target
+19.01%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Krystal Biotech, Inc.
  1. Stock Market
  2. Stocks
  3. KRYS Stock